Objectives:To evaluate the diagnostic value of WFA+-M2BP in patients with hepatic fibrosis or liver cirrhosis.Methods:A literature search was conducted from the PubMed,Ovid and China Biological Medicine Database (CBM),VIP data network (VIP).The databases were used to identify the Chinese or English literature which were related with the use of WFA+-M2BP in the diagnosis of patients with hepatic fibrosis or liver cirrhosis.The software-Stata version 13.0 was used to analyze the data.Results:A total of six English articles involving 927 patients were identified.The results showed that:(1)The results of Sen,Spe,+LR,-LR,DOR,AUC for WFA+-M2BP to diagnose advanced hepatic fibrosis were 0.78[95%CI(0.67~0.86)],0.86[95%CI(0.77~0.92)],5.50[95%CI(3.60~8.60)],0.26[95%CI(0.18~0.37)],22[95%CI(14~34)] and 0.89[95%CI(0.86~0.91)],respectively.(2)The results of Sen,Spe,+LR,-LR,DOR,AUC for WFA+-M2BP to diagnose early-stage liver cirrhosis were 0.85[95%CI(0.70~0.94)],0.90[95%CI(0.62~0.98)],8.40[95%CI(2.10~33.6)],0.16[95%CI(0.08~0.32)],51[95%CI(17~151)] and 0.92[95%CI(0.90~0.94)],respectively.Conclusion:WFA+-M2BP has a high diagnostic value for hepatic fibrosis and liver cirrhosis. |
[1] 陈永鹏,汪艳,金林.肝纤维化/肝硬化的动态变化及其诊断进展[J].中华肝脏病学杂志,2015,23(4):244-246.
[2] 盛婷,傅念,阳学风.肝纤维化发病机制中细胞和分子机制的研究进展[J].现代生物医学进展,2015,15(12):2358-2362.
[3] 范慧宁,陈尼维.肝纤维化的流行病学研究进展[J].国际消化病杂志,2014,34(1):29-31.
[4] 朱传龙,王坤,高人焘.肝纤维化无创性诊断技术的临床应用[J].临床肝胆病杂志,2015,31(3):332-336.
[5] KAMIYAMA T,YOKOO H,FURUKAWA J,et al.Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis[J].Hepatology,2013,57(6):2314-2325.
[6] NARIMATSU H.Development of M2BPGi:a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics[J].Expert Rev Proteomics,2015,12(6):683-690.
[7] HANAI T,SHIRAKI M,OHNISHI S,et al.Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis[J].Hepatology Research,2015,45:1082-1090.
[8] ZHOU D,WANG Y,ZHANG W,et al.WFA+-M2BP:a novel biomarker with diagnostic and therapeutic implications in liver diseases[J].Liver Inter,2016,26(4):612.
[9] IWATA K,ENOMOTO H,NISHIGUCHI S.et al.Serum zinc value in patients with hepatitis virus-related chronic liver disease:association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis[J].Clin Biochem Nutr,2014,55(2):147-152.
[10] KUNO A,IKEHARA Y,ITO K,et al.A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis[J].Scientific Reports,2013,3:1065.
[11] TOSHIMA T,SHIRABE K,IKEGAMI T,et al.A novel serum marker,glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP),for assessing liver fibrosis[J].J Gastroenterol,2015,50(1):76-84.
[12] ABE M,MIYAKE T,KUNO A,et al.Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease[J].J Gastroenterol,2015,50(7):776-784.
[13] NISHIKAWA H,ENOMOTO H,IWATA Y.et al.Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-γ-inducible protein-10 in primary biliary cirrhosis[J].Hepatol Res,2016,46(6):575-583.
[14] NISHIKAWA H,ENOMOTO H,IWATA Y.et al.Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis[J].Hepatol Res,2016,46(7):613-621.
[15] UMEMURA T,JOSHITA S,SEKIGUCHI T.Serum Wisteria floribunda Agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis[J].Am J Gastroenterol,2015,110(6):857-864.
[16] KUNO A,SATO T,SHIMAZAKI H,et al.Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling[J].Proteomics Clin App,2013,7(9-10):642-647.
[17] YAMASAKI K,TATEYAMA M,ABIRU S,et al.Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients[J].Hepatology,2014,60(5):1563-1570. |